Investing.com UK - Financial Markets Worldwide
Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Celgene readies deal to buy Impact Biomedicines for as much as $7 billion - WSJ

Published 07/01/2018, 21:32
Updated 07/01/2018, 21:40
© Reuters. Celgene readies deal to buy Impact Biomedicines for as much as $7 billion - WSJ
CELG
-

NEW YORK (Reuters) - Celgene Corp (NASDAQ:CELG) is expected to announce Monday that it is acquiring Impact Biomedicines for as much as $7 billion (£5.1 billion), the Wall Street Journal reported Sunday.

Sources tell the publication that the potential deal could involve an upfront payment of $1 billion for the privately held California-based company. Subsequent components of the deal would depend on approval from the Food and Drug Administration and successful acceptance in the market, according to the publication.

Celgene and Impact Biomedicines did not immediately respond to requests for comment.

Celgene is bio-technology company based in Summit, New Jersey, that specializes in treatments for multiple myeloma. Impact Biomedicines focuses on treatments for patients with related cancers that are classified as myeloproliferative neoplasms, according to the company's website.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.